Valuation: Moderna, Inc.

Market Cap 25.28B 21.83B 20.52B 18.66B 35.08B 2,417B 35.66B 240B 93.99B 1,211B 94.91B 92.85B 4,023B P/E 2026 *
-7.38x
P/E 2027 * -12.9x
Enterprise Value 21.63B 18.68B 17.56B 15.97B 30.02B 2,068B 30.51B 206B 80.43B 1,036B 81.21B 79.45B 3,442B EV / Sales 2026 *
10.3x
EV / Sales 2027 * 9.47x
Free-Float
92.68%
Yield 2026 *
-
Yield 2027 * -
1 day-0.52%
1 week+7.01%
Current month+15.51%
1 month-7.26%
3 months+29.12%
6 months+49.94%
Current year+114.72%
1 week 58.41
Extreme 58.41
65.33
1 month 52.66
Extreme 52.6601
65.33
Current year 29.81
Extreme 29.81
85.6
1 year 22.28
Extreme 22.28
85.6
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
464.85
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 28/02/2011
Director of Finance/CFO 49 05/09/2022
President 50 31/10/2024
Director TitleAgeSince
Chairman 63 31/01/2012
Director/Board Member 54 28/02/2011
Director/Board Member 69 10/12/2019
Date Insider Type Main position Quantity % Market Cap.
06/08/26 Fiscal year

Chief Executive Officer

504,938 0.1273%
15/07/26 Fiscal year

Chairperson

160,008 0.0403%
08/07/26 Free

Director

14,766 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
-0.52%+7.01%+125.98%-34.32% 25.28B
-0.31%+2.44%+38.43%-0.30% 80.23B
-1.02%-0.51%-2.54%+26.80% 50.64B
-3.10%-4.84%+10.29%+158.34% 46.87B
-0.74%+3.26%-49.51%-49.96% 46.34B
-0.39%+0.91%+51.39%-22.35% 31B
-0.30%-0.33%+38.24%+83.70% 24.36B
-1.42%-1.11%-3.79%+190.40% 20.81B
-1.83%-2.82%+60.85%+107.54% 16.08B
-1.66%-5.47%+55.61%+162.18% 15.61B
Average -1.13%+0.75%+32.49%+62.20% 35.72B
Weighted average by Cap. -1.05%+0.84%+24.13%+42.38%

Financials

2026 *2027 *
Net sales 2.11B 1.82B 1.71B 1.55B 2.92B 201B 2.97B 20.03B 7.83B 101B 7.91B 7.74B 335B 2.43B 2.1B 1.97B 1.79B 3.37B 232B 3.43B 23.09B 9.03B 116B 9.12B 8.92B 386B
Net income -3.38B -2.92B -2.74B -2.49B -4.69B -323B -4.77B -32.13B -12.56B -162B -12.69B -12.41B -538B -1.92B -1.66B -1.56B -1.42B -2.67B -184B -2.71B -18.3B -7.15B -92.13B -7.22B -7.07B -306B
Net Debt -3.65B -3.15B -2.96B -2.69B -5.06B -349B -5.15B -34.7B -13.57B -175B -13.7B -13.4B -581B -2.27B -1.96B -1.84B -1.68B -3.15B -217B -3.2B -21.6B -8.45B -109B -8.53B -8.34B -361B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
14/08/26 US$63.32 -0.52% 4,700,891
13/08/26 US$63.65 -0.03% 8,159,738
12/08/26 US$63.67 +5.12% 6,581,997
11/08/26 US$60.57 +1.27% 6,556,326
10/08/26 US$59.81 +1.08% 6,224,525
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
63.32USD
Average target price
50.84USD
Spread / Average Target
-19.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock